Ovarian cancer
Results
Phase 2
This trial looked at a drug called etirinotecan pegol (also known as NKTR-102) for women with ovarian cancer. The trial was for women with:
Their cancer had come back despite having other treatment and could not be removed with surgery.
These cancers are all treated in the same way, so when we use the term ovarian cancer in this summary, we are referring to all 3.
Recruitment start: 15 July 2009
Recruitment end: 2 March 2012
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Nick Reed Professor Hilary Calvert
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
Nektar Therapeutics
Last reviewed: 19 December 2014
CRUK internal database number: 5711
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
